Literature DB >> 9015211

Stem cell transplantation in the normal nonmyeloablated host: relationship between cell dose, schedule, and engraftment.

S S Rao1, S O Peters, R B Crittenden, F M Stewart, H S Ramshaw, P J Quesenberry.   

Abstract

In previous studies we have shown high rates of stable engraftment when 40 million male BALB/c cells were infused intravenously daily for 5 days (a total of 200 million cells) to normal nonmyeloablated female hosts. The present studies evaluate engraftment of male BALB/c bone marrow cells in female host marrow, spleen, and thymus 20-25 weeks after transplantation using varying cell dosages within a 5-day schedule. Engraftment in recipient mice was assessed by detection of male specific sequence in recipient DNA from each organ. When 40 million cells were given per daily injection for 1, 2, 3, 4, or 5 days, engraftment percentages in host marrow were 11 +/- 0.83, 20 +/- 2.0, 23 +/- 2.5, 32 +/- 6.3, and 39% +/- 5.7 (+/- standard error of mean), respectively, yielding engraftment percentages per million cells infused of 0.28, 0.25, 0.19, 0.20, and 0.20%, respectively. When levels of 2.5, 5, 10, 20, or 40 million cells were injected 5 times over a 5-day schedule into normal BALB/c female hosts, progressively increasing levels of engraftment from 3 +/- 0.6 to 39% +/- 5.7 were seen in host marrow. Highest levels of engraftment per million cells injected were obtained on days 1 and 2 of a 5-day schedule and with a level of 10 million cells given daily over 5 days. Engraftment profiles varied with spleen and thymus and percent engraftment was generally lower than for marrow. The present work indicates that regardless of cell level infused or number of infusions, rates of engraftment observed in marrow approached or exceeded the highest rates of engraftment estimated by theoretical calculations based on replacing host cells ("replacement model") or adding to host cells ("incremental model"). Engraftment in spleen and thymus was lower, but also at times approached or exceeded theoretical maxima. These data show extraordinary levels of engraftment in normal hosts, suggesting that rates in this competitive model are superior to those seen in irradiated hosts; alternatively, there may be selective repression of host stem cell proliferation and differentiation.

Entities:  

Mesh:

Year:  1997        PMID: 9015211

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  23 in total

1.  VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients.

Authors:  Pampee P Young; A Alex Hofling; Mark S Sands
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-23       Impact factor: 11.205

2.  The new stem cell biology.

Authors:  Peter J Quesenberry; Gerald A Colvin; Jean-Francois Lambert; Angela E Frimberger; Mark S Dooner; Christina I Mcauliffe; Caroline Miller; Pamela Becker; Evangelis Badiavas; Vincent J Falanga; Gerald Elfenbein; Lawrence G Lum
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 3.  Bone marrow-derived stem cell transplantation for the treatment of insulin-dependent diabetes.

Authors:  Carmen Fotino; Camillo Ricordi; Vincenzo Lauriola; Rodolfo Alejandro; Antonello Pileggi
Journal:  Rev Diabet Stud       Date:  2010-08-10

4.  Rapid lymphocyte reconstitution of unconditioned immunodeficient mice with non-self-renewing multipotent hematopoietic progenitors.

Authors:  Deepta Bhattacharya; David Bryder; Derrick J Rossi; Irving L Weissman
Journal:  Cell Cycle       Date:  2006-06-01       Impact factor: 4.534

5.  Mobilization as a preparative regimen for hematopoietic stem cell transplantation.

Authors:  Jing Chen; André Larochelle; Simon Fricker; Gary Bridger; Cynthia E Dunbar; Janis L Abkowitz
Journal:  Blood       Date:  2006-01-26       Impact factor: 22.113

Review 6.  Stem cell homing: rolling, crawling, and nesting.

Authors:  P J Quesenberry; P S Becker
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

7.  Chiaroscuro hematopoietic stem cell.

Authors:  P Quesenberry; M Habibian; M Dooner; S Zhong; J Reilly; S Peters; P Becker; C Grimaldi; J Carlson; P Reddy; S Nilsson; F M Stewart
Journal:  Trans Am Clin Climatol Assoc       Date:  1998

Review 8.  The potential of non-myeloablative heterochronous autologous hematopoietic stem cell transplantation for extending a healthy life span.

Authors:  Primož Rožman
Journal:  Geroscience       Date:  2018-06-14       Impact factor: 7.713

9.  Niche recycling through division-independent egress of hematopoietic stem cells.

Authors:  Deepta Bhattacharya; Agnieszka Czechowicz; A G Lisa Ooi; Derrick J Rossi; David Bryder; Irving L Weissman
Journal:  J Exp Med       Date:  2009-11-02       Impact factor: 14.307

10.  Transfer of hematopoietic stem cells encoding autoantigen prevents autoimmune diabetes.

Authors:  Raymond J Steptoe; Janine M Ritchie; Leonard C Harrison
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.